The impact of body mass index on efficacy and safety in the tofacitinib OCTAVE ulcerative colitis clinical programme

BACKGROUND: Obesity may affect efficacy and safety of biologic treatments for ulcerative colitis (UC). Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of UC. AIMS: To assess efficacy and safety of tofacitinib in patients with UC, by baseline body mass index (BMI). MET...

Descripción completa

Detalles Bibliográficos
Autores principales: Farraye, Francis A., Qazi, Taha, Kotze, Paulo G., Moore, Gregory T., Mundayat, Rajiv, Lawendy, Nervin, Sharma, Puza P., Judd, Donna T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Bmi and Tofactinib Efficacy in Uc
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8362064/
https://www.ncbi.nlm.nih.gov/pubmed/34165201
http://dx.doi.org/10.1111/apt.16439

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8362064/
https://www.ncbi.nlm.nih.gov/pubmed/34165201
http://dx.doi.org/10.1111/apt.16439

Ejemplares similares